📣 VC round data is live. Check it out!

NovoCure Valuation Multiples

Discover revenue and EBITDA valuation multiples for NovoCure and similar public comparables like Bausch Health, Establishment Labs, Jeol, AddLife and more.

NovoCure Overview

About NovoCure

NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.


Founded

2000

HQ

United States

Employees

1.5K

Financials (LTM)

Revenue: $674M
EBITDA: ($23M)

EV

$2B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

NovoCure Financials

NovoCure reported last 12-month revenue of $674M and negative EBITDA of ($23M).

In the same LTM period, NovoCure generated $506M in gross profit, ($23M) in EBITDA losses, and had net loss of ($154M).

Revenue (LTM)


NovoCure P&L

In the most recent fiscal year, NovoCure reported revenue of $655M and EBITDA of ($34M).

NovoCure is unprofitable as of last fiscal year, with gross margin of 75%, EBITDA margin of (5%), and net margin of (21%).

See analyst estimates for NovoCure
LTMLast FY202320242025202620272028
Revenue$674M$655M$509M$605M$655M
Gross Profit$506M$488M$381M$468M$488M
Gross Margin75%75%75%77%75%
EBITDA($23M)($34M)($177M)($110M)($105M)
EBITDA Margin(3%)(5%)(35%)(18%)(16%)
EBIT Margin(24%)(23%)(46%)(28%)(23%)
Net Profit($154M)($136M)($207M)($169M)($136M)
Net Margin(23%)(21%)(41%)(28%)(21%)
Net Debt$101M

Financial data powered by Morningstar, Inc.

NovoCure Stock Performance

NovoCure has current market cap of $2B, and enterprise value of $2B.

Market Cap Evolution


NovoCure's stock price is $17.01.

NovoCure share price increased by 11.9% in the last 30 days, and decreased by 11.0% in the last year.

NovoCure has an EPS (earnings per share) of $-1.18.

See more trading valuation data for NovoCure
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$2B$2B-2.5%11.9%24.4%-11.0%$-1.18

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

NovoCure Valuation Multiples

NovoCure trades at 2.6x EV/Revenue multiple, and (76.1x) EV/EBITDA.

See NTM and 2027E valuation multiples for NovoCure

EV / Revenue (LTM)


NovoCure Financial Valuation Multiples

As of May 20, 2026, NovoCure has market cap of $2B and EV of $2B.

NovoCure has a P/E ratio of (12.8x).

LTMLast FY202320242025202620272028
EV/Revenue2.6x2.7x3.5x2.9x2.7x
EV/EBITDA(76.1x)(51.7x)(10.0x)(16.2x)(17.0x)
EV/EBIT(11.1x)(11.5x)(7.6x)(10.4x)(11.5x)
EV/Gross Profit3.5x3.6x4.7x3.8x3.6x
P/E(12.8x)(14.5x)(9.5x)(11.7x)(14.5x)
EV/FCF(25.7x)(23.4x)(17.7x)(25.6x)(23.4x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified NovoCure Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

NovoCure Margins & Growth Rates

NovoCure grew revenue by 7% but EBITDA decreased by 84% in the last fiscal year.

In the most recent fiscal year, NovoCure reported gross margin of 75%, EBITDA margin of (5%), and net margin of (21%).

See estimated margins and future growth rates for NovoCure

NovoCure Margins

Last FY202420252026202720282029
Gross Margin75%77%75%76%
EBITDA Margin(5%)(18%)(16%)(1%)
EBIT Margin(23%)(28%)(23%)(24%)
Net Margin(21%)(28%)(21%)(26%)
FCF Margin(12%)(11%)(12%)(8%)

NovoCure Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth7%19%8%7%
Gross Profit Growth10%23%4%10%
EBITDA Growth(84%)(38%)(5%)(95%)
EBIT Growth9%(27%)(10%)9%
Net Profit Growth35%(19%)(19%)35%
FCF Growth(23%)(31%)9%(23%)

Data powered by FactSet, Inc. and Morningstar, Inc.

NovoCure Operational KPIs

NovoCure's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.4M for the same period.

NovoCure's Rule of 40 is 7% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

NovoCure's Rule of X is 18% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for NovoCure
LTMLast FY202320242025202620272028
Rule of 405%7%
Bessemer Rule of X18%18%
Revenue per Employee$0.4M
Opex per Employee$0.4M
S&M Expenses to Revenue36%37%45%40%37%
G&A Expenses to Revenue29%27%32%31%27%
R&D Expenses to Revenue34%34%44%35%34%
Opex to Revenue98%121%106%98%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

NovoCure Competitors

NovoCure competitors include Bausch Health, Establishment Labs, Jeol, AddLife, Beijing Balance Medical, MicroPort Scientific, Fukuda Denshi, GN Store Nord, MicroPort EP and MicroPort.

Most NovoCure public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Bausch Health2.1x2.1x6.1x5.9x
Establishment Labs10.1x9.1x(149.8x)(1019.3x)
Jeol1.6x1.7x10.2x9.7x
AddLife2.0x2.0x12.1x12.4x
Beijing Balance Medical20.7x51.3x
MicroPort Scientific2.4x2.4x16.7x13.9x
Fukuda Denshi1.7x1.7x6.3x
GN Store Nord1.3x1.3x8.5x9.3x

This data is available for Pro users. Sign up to see all NovoCure competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About NovoCure

When was NovoCure founded?NovoCure was founded in 2000.
Where is NovoCure headquartered?NovoCure is headquartered in United States.
How many employees does NovoCure have?As of today, NovoCure has over 1K employees.
Who is the CEO of NovoCure?NovoCure's CEO is Francis Leonard.
Is NovoCure publicly listed?Yes, NovoCure is a public company listed on Nasdaq.
What is the stock symbol of NovoCure?NovoCure trades under NVCR ticker.
When did NovoCure go public?NovoCure went public in 2015.
Who are competitors of NovoCure?NovoCure main competitors include Bausch Health, Establishment Labs, Jeol, AddLife, Beijing Balance Medical, MicroPort Scientific, Fukuda Denshi, GN Store Nord, MicroPort EP, MicroPort.
What is the current market cap of NovoCure?NovoCure's current market cap is $2B.
What is the current revenue of NovoCure?NovoCure's last 12 months revenue is $674M.
What is the current revenue growth of NovoCure?NovoCure revenue growth (NTM/LTM) is 9%.
What is the current EV/Revenue multiple of NovoCure?Current revenue multiple of NovoCure is 2.6x.
Is NovoCure profitable?No, NovoCure is not profitable.
What is the current EBITDA of NovoCure?NovoCure has negative EBITDA and is not profitable.
What is NovoCure's EBITDA margin?NovoCure's last 12 months EBITDA margin is (3%).
What is the current EV/EBITDA multiple of NovoCure?Current EBITDA multiple of NovoCure is (76.1x).
What is the current FCF of NovoCure?NovoCure's last 12 months FCF is ($69M).
What is NovoCure's FCF margin?NovoCure's last 12 months FCF margin is (10%).
What is the current EV/FCF multiple of NovoCure?Current FCF multiple of NovoCure is (25.7x).
How many companies NovoCure has acquired to date?NovoCure hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies NovoCure has invested to date?NovoCure hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to NovoCure

Lists including NovoCure

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial